Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Jump to bottom

VAC: Nexavant #694

Closed
nkosar opened this issue Mar 21, 2024 · 2 comments
Closed

VAC: Nexavant #694

nkosar opened this issue Mar 21, 2024 · 2 comments

Comments

@nkosar
Copy link

nkosar commented Mar 21, 2024

Request to add a new vaccine adjuvant as seen in VAC:
https://vac.niaid.nih.gov/view?id=94

Chemical Nature: dsRNA
Mechanism of Action: TLR3 agonist
Immune profile induced: Mixed Th1/Th2
Definition:

  • category: nucleic-acid based adjuvant (TLR-agonist)
  • synthetic derivative of natural compound

Route of immunization: IM
Point of Contact: Seungbin Cha, NA Vaccine Institute

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=36761735
https://www.ncbi.nlm.nih.gov/pubmed/?term=38136298

Ongoing clinical trials:
none
@zhengj2007
Copy link
Contributor

Added 'nexavant vaccine adjuvant' with ID: VO:0006108

@zhengj2007 zhengj2007 mentioned this issue Apr 9, 2024
Merged
@zhengj2007
Copy link
Contributor

@nkosar The term is available on the ontobee: nexavant vaccine adjuvant.

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
Assignees
No one assigned
Labels
None yet
Projects
None yet
Milestone
No milestone
Development

No branches or pull requests
2 participants
@zhengj2007 @nkosar